FDA Approved: ERLEADA — Supplemental Application (Janssen Products, LP)

View source ↗

Summary

The FDA approved a supplemental application for ERLEADA (apalutamide) submitted by Janssen Products, LP, resulting in an expanded or updated indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Non-metastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

SUPPL AP for ERLEADA (APALUTAMIDE)